News Room
Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Advanced Liver Cancer
BAYER TO PRESENT DATA ON INVESTIGATIONAL PULMONARY HYPERTENSION COMPOUND RIOCIGUAT AT ATS 2013
Bayer to acquire Conceptus, Inc.
Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST
U.S. FDA Grants Priority Review to Bayer's Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
Bayer Submits New Drug Application for Radium Ra 223 Dichloride for the Treatment of Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases
Bayer's Second Annual Virtual Walk for Hemophilia Raises Funds, Generates Excitement in the Hemophilia Community
Phase 3 Study EvaluatesTwo Investigational Hormone-Releasing IUDs for Prevention of Pregnancy for up to Three Years
Bayer's Investigational Riociguat Meets Primary Endpoint in Phase III Study in Patients with Pulmonary Arterial Hypertension (PAH)
BAYER TO PRESENT DATA ON INVESTIGATIONAL PULMONARY HYPERTENSION COMPOUND AT CHEST 2012
Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Bayer Submits New Drug Application for Regorafenib for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Bayer Submits New Drug Application for Regorafenib for the Treatment of Metastatic Colorectal Cancer
U.S. FDA APPROVES FIRST AND ONLY ORAL CONTRACEPTIVE DEMONSTRATED TO TREAT HEAVY MENSTRUAL BLEEDING(HMB)
U.S. FDA APPROVES LOWER DOSE FORMULATION OF ANGELIQ® (DROSPIRENONE AND ESTRADIOL) TABLETS
BAYER EXPANDS ITS HEMOPHILIA LEADERSHIP DEVELOPMENT PROGRAM Company Seeking Applicants for Prestigious Summer Internship
Bayer Initiates Expanded Access Program for Investigational Compound Radium-223 Chloride
January 17, 2012 - Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), LBA #385:
Phase III Data Show Bayer?s Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in
Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapies
Wayne, NJ, January 17, 2012 ? Bayer HealthCare today announced latest data on its investigational compound regorafenib (BAY 73-4506) from the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial.
See More
January 10, 2012 - Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI):
Phase III Data on Bayer?s Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
Wayne, NJ, January 10, 2012 ? Bayer HealthCare today announced that results from the Phase III CORRECT study will be presented as a late breaking abstract in an oral abstract session on January 21 (2:30 p.m. ? 4:00 p.m. PT, Level 3 Ballroom, Moscone Center West) at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.
See More
December 8, 2011 - Bayer's drospirenone-containing combination oral contraceptives:
FDA Advisory Committees affirm positive benefit-risk profile and
recommend an update of labels to reflect information from available
studies
Wayne, NJ, December 8, 2011 ? Bayer HealthCare Pharmaceuticals, Inc. today announced that at a joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA), the majority of Advisory Committee members voted (15 to 11) that the benefits of drospirenone-containing combination oral contraceptives (COCs) in the prevention of pregnancy outweigh the potential risks.
See More
November 11, 2011 - BAYER VIRTUAL WALK FOR HEMOPHILIA RAISES AWARENESS AND FUNDS FOR PEOPLE
WITH BLEEDING DISORDERS
Unique Interactive Contest Benefits Hemophilia Communities Across the Country
CHICAGO, November 11, 2011 ? At a special ceremony at the National Hemophilia Foundation (NHF) Annual Meeting in Chicago, Bayer HealthCare and members of the hemophilia community commemorated the successful conclusion of Bayer?s first Virtual Walk for Hemophilia
See More
October 26, 2011 - Phase III Trial of Bayer?s Investigational Compound Regorafenib (BAY 73-4506) in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival
Wayne, NJ, October 26, 2011 ? Bayer HealthCare Pharmaceuticals today announced results from its Phase III trial evaluating its investigational compound regorafenib
See More
October 12, 2011 - Bayer HealthCare and Onyx Pharmaceuticals Restructure Global Oncology Partnership
San Francisco, CA, USA, October 12, 2011 ? Today Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) restructured their partnership for the global development and marketing of Nexavar?
See More
September 23, 2011 - Positive Phase III Data on Bayer?s Investigational Drug Radium-223 Chloride Show Significant Increase in Overall Survival
Wayne, NJ, September 23, 2011 ? Bayer HealthCare Pharmaceuticals today announced that the investigational drug radium-223 chloride showed positive data in the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial.
See More
September 13, 2011 - Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
Wayne, NJ, September 13, 2011 ? Bayer HealthCare announced today that the company will present data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.
See More
June 6, 2011 - Bayer?s Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Wayne, NJ, June 6, 2011 ? Bayer HealthCare Pharmaceuticals Inc. today announced that the Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial evaluating Bayer?s investigational compound, radium-223 chloride, which is exclusively licensed from Algeta ASA, in patients with castration-resistant prostate cancer (CRPC) and bone metastases met its primary endpoint by significantly improving overall survival.
See More
May 18, 2011 - Nexavar Data To Be Presented at American Society of Clinical Oncology Annual Meeting
Wayne, NJ and San Francisco, CA, May 18, 2011 ? Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that data evaluating the use of Nexavar? (sorafenib) tablets will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago.
See More
May 18, 2011 - Bayer to Present Data on Investigational Oncology Compounds at 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Wayne, NJ, May 18, 2011 ? Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7, in Chicago, IL.
See More
May 10, 2011 - FDA Grants Fast Track Designation to Bayer?s Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Wayne, NJ, May 10, 2011 ? Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and sunitinib as prior treatments.
See More
April 25, 2011 - KOGENATE? FS, ANTIHEMOPHILIC FACTOR (RECOMBINANT), FOR HEMOPHILIA A NOW EASIER FOR PEOPLE TO STORE AT HOME OR ON THE GO
Room Temperature Storage Up to 77? F for One Year Provides Added Convenience
Wayne, NJ, April 25, 2011 ? Bayer HealthCare Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved a new storage option for Kogenate? FS, antihemophilic factor (recombinant), now allowing the product to be stored at room temperature (up to 77? F) for up to one year. Compared with the previous three-month room temperature option, this new storage option for Kogenate FS offers added convenience for patients with hemophilia A and is immediately available to customers.
See More
April 21, 2011 - BAYER AFFIRMS BENEFIT-RISK PROFILE OF ITS ORAL CONTRACEPTIVES
Established body of well grounded data show VTE risk comparable in combined oral contraceptives studied
Wayne, NJ, April 21, 2011 ? Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.
See More
April 14, 2011 - BAYER LAUNCHES FIRST INTERACTIVE VIRTUAL WALK IN SUPPORT OF HEMOPHILIA
Company to Give Sponsorship Funds to National and Local Hemophilia Groups
Wayne, NJ, April 14, 2011 ? To help raise money and awareness for bleeding disorders, Bayer is launching the 2011 Bayer Virtual Walk for Hemophilia, the first interactive program of its kind in support of people with hemophilia. The Virtual Walk is Bayer?s latest digital offering for the hemophilia community. The company is asking people to step up for an important cause by virtually walking online for the National Hemophilia Foundation (NHF) and its local participating chapters. The company is offering up to $60,000 in sponsorship funds, and is kicking off the Virtual Walk in concert with World Hemophilia Day (WHD) and a 5k walk in Berkeley, Calif.
See More
April 4, 2011 - BAYER HEALTHCARE SELECTS THE STATE OF NEW JERSEY FOR EAST COAST SITE CONSOLIDATION
Wayne, NJ, April 4, 2011 ? Bayer HealthCare and the Governor of New Jersey, Chris Christie, are proud to announce that the company has selected New Jersey as the new "home" of Bayer HealthCare's consolidated East-Coast business site.
See More
March 25, 2011 - NEW INTERIM DATA ABOUT COMBINATION ORAL CONTRACEPTIVES
WAYNE, N.J., March 25, 2011 - Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".
See More
March 15, 2011 - TV PERSONALITY VANESSA MINNILLO TEAMS UP WITH BAYER AND MARCH OF DIMES TO LAUNCH NATIONAL FOLATE AWARENESS CAMPAIGN
WHITE PLAINS, N.Y. and WAYNE, N.J., March 15, 2011 - Vanessa Minnillo is making it a priority to share an important public health message with women nationwide.
See More
March 14, 2011 - U.S. FDA Approves Bayer?s Gadavist? (Gadobutrol) Injection for MRI of the Central Nervous System
Wayne, NJ, March 14, 2011 - Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist? (gadobutrol) Injection, a macrocyclic gadolinium-based contrast agent (GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system (CNS).
See More
February 4, 2011 - FDA Grants Orphan Drug Designation to Bayer?s Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
Wayne, NJ, February 4, 2011 - Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA).
See More
January 10, 2011 - Bayer HealthCare Marks Opening of U.S. Innovation Center
San Francisco, CA, USA, January 10, 2011 - Bayer HealthCare announced today that its pharmaceutical division has established a master agreement for research collaborations with the University of California, San Francisco (UCSF).
See More
January 08, 2011 - Important Information for Betaseron? (interferon beta 1-b) Consumers
Regarding Triad Group?s Alcohol Prep Products
Wayne, NJ, January 8, 2011 - Bayer HealthCare Pharmaceuticals has become aware of a broad United States market recall of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. In the interest of patient safety
See More
December 16, 2010 - U.S. FDA APPROVES SECOND BAYER ORAL CONTRACEPTIVE THAT ALSO RAISES FOLATE LEVELS
Wayne, NJ, December 16, 2010 - Bayer continues to drive innovation through portfolio of oral contraceptives (OCs) offering daily folate supplementation for women who choose an OC for contraception
See More
September 24, 2010 - U.S. FDA APPROVES NEW ORAL CONTRACEPTIVE THAT ALSO RAISES FOLATE LEVELS
First and only FDA-approved birth control pill with four indications
Wayne, NJ, September 24, 2010 - Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), BeyazTM(drospirenone / ethinyl estradiol / levomefolate calcium tablets and levomefolate calcium tablets).
See More
June 28, 2010 - Bayer HealthCare Introduces First Mobile Application
to Assist Hemophilia A Patients in Managing their Treatment
Wayne, NJ, USA June 15, 2010 - Bayer HealthCare Pharmaceuticals today launched FactorTrackTM, the first customizable mobile application for people with hemophilia A. FactorTrack is a free, personal and interactive mobile application that helps make it easier to track and record hemophilia factor VIII infusions.
See More
June 17, 2010 - Teva Admits to Making False Statements in US GianviTM
Label and Agrees to Corrective Measures
Wayne, NJ, USA June 17, 2010 - Bayer's lawsuit under the Federal False Advertising Act (the Lanham Act) results in Teva agreement to make three months of weekly communications to pharmacists to correct false labels.
See More
June 15, 2010 - Bayer Sues Teva and Barr for False Advertising and
Patent Infringement in Connection with Teva?s Generic
Oral Contraceptive GianviTM
Wayne, NJ, USA June 15, 2010 - Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva?s generic oral contraceptive, Gianvi?. Teva?s product is sold as a generic version of Bayer HealthCare?s leading oral contraceptive YAZ?.
See More
June 14, 2010 - Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell
Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Wayne, NJ and Emeryville, CA - Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar? (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.
See More
May 17, 2010 - Bayer HealthCare Enhances U.S. Research Strategy with New Innovation Center
Berlin, Germany and San Francisco, CA, USA, May 17, 2010 - Bayer HealthCare?s pharmaceutical division will establish a U.S. Innovation Center in San Francisco, Calif. to bundle its US research activities and to expand its global research network with the goal of expanding its specialty pharmaceutical pipeline.
See More
May 6, 2010 - U.S. FDA APPROVES NATAZIA?, A NEW ORAL CONTRACEPTIVE
FOR THE PREVENTION OF PREGNANCY
Wayne, New Jersey, May 6, 2010 - Bayer HealthCare Pharmaceuticals, Inc. (NYSE: BAYER AG) today announced that the U.S. Food and Drug Administration (FDA) has approved NataziaTM (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.
See More
April 17, 2010 - Bayer HealthCare Marks 2010 World Hemophilia Day
with a $350,000 Contribution to the World Federation of Hemophilia
MONTVILLE, New Jersey, April 17, 2010 - To mark World Hemophilia Day, Bayer HealthCare is reaffirming its commitment to the global hemophilia community by pledging more than $350,000 to the World Federation of Hemophilia (WFH) and participating in the Hemophilia Walk of the National Hemophilia Foundation (NHF).
See More
April 9, 2010 - BAYER UPDATES LABELS FOR YAZ and YASMIN
Body of Evidence Affirms VTE Risk/Benefit Profile for YAZ and Yasmin Is Comparable to
Other Combination Oral Contraceptives
Wayne, New Jersey, April 9, 2010 - In full agreement with the U.S. Food and Drug Administration (FDA), Bayer HealthCare Pharmaceuticals, Inc. today announced that it will update the labels for YAZ? (3 mg drospirenone / 0.02 mg ethinyl estradiol) and Yasmin? (3 mg drospirenone / 0.03 mg ethinyl estradiol) in the United States.
See More
March 11, 2010 - FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler
for the Treatment of Cystic Fibrosis
Wayne, New Jersey, March 11, 2010 -? Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients.
See More
December 10, 2009 - Bayer HealthCare Donates to Community Food Bank of New Jersey
Wayne and Morristown, NJ, December 10, 2009 - Bayer HealthCare Pharmaceuticals (BHCP) has donated over 1,100 pounds of food to the Community FoodBank of New Jersey through a company food drive. In addition, Bayer will provide a $20,000 monetary donation to the Community FoodBank.
See More
December 1, 2009 - NATIONAL SURVEY REVEALS PEOPLE WITH MULTIPLE SCLEROSIS ARE CONCERNED
ABOUT DISEASE?S IMPACT ON RELATIONSHIPS AND CAREERS
Wayne, NJ, December 1, 2009 - A survey among 100 Americans with multiple sclerosis (MS) shows that many face similar life challenges when newly diagnosed with the disease.
See More
November 30, 2009 - Bayer HealthCare Pharmaceuticals Inc. Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer?s Disease
Wayne, New Jersey and Chicago, November 30, 2009 - Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease.
See More
October 1, 2009 - FDA APPROVES NEW INDICATION FOR MIRENA®
TO TREAT HEAVY MENSTRUAL BLEEDING IN IUD USERS
Wayne, NJ, October 1, 2009 - Bayer HealthCare Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for Mirena® (levonorgestrel-releasing intrauterine system) for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena provides an effective, non-surgical option for the treatment of heavy menstrual bleeding and is the first and only contraceptive approved in the U.S. for this indication.
See More
August 7, 2009 - FDA Approves New 3000 IU Vial Size for Kogenate® FS, antihemophilic factor (recombinant)
WAYNE, NJ, August 7, 2009 - Today, Bayer HealthCare Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved a 3000 IU (international unit) vial size of Kogenate® FS, antihemophilic factor (recombinant).
See More
July 9, 2009 - Bayer HealthCare Launches Hemophilia Self-Infusion Training Program
WAYNE, NJ, July 9, 2009 - Today, Bayer HealthCare Pharmaceuticals launched the BayCuff? self-infusion training program, an educational initiative designed to make infusion of recombinant factor VIII easier for both patients with hemophilia A and for their caregivers.
See More
May 30, 2009 - Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Orlando, FL, USA, May 30, 2009 - Bayer today announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
See More
May 29, 2009 -Bayer Announces Leukine® Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
WAYNE, N.J. May 29, 2009 - Bayer Healthcare Pharmaceuticals Inc. today announced that several studies evaluating the use of Leukine® (sargramostim) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting.
See More
May 28, 2009 - Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer.
WAYNE, N.J., EMERYVILLE, Calif. and MELVILLE, N.Y.Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
See More
April 29, 2009 - New Analyses from 16-Year Follow-up Trial with Betaseron? Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes .
Seattle, Wash.New analyses of data from the 16-Year Long-term Follow-up study with Betaseron? (interferon beta-1b), sponsored by Bayer HealthCare Pharmaceuticals, were presented at the American Academy of Neurology?s (AAN) 61st Annual Meeting.
See More
December 2, 2008 - JENNIE FINCH SHARES HOW TO FIRE UP THE ROMANCE DESPITE THE DEMANDS OF THE HOLIDAYS.
Wayne, NJWith the bright lights, sweet treats and beautifully wrapped gifts, the winter holidays may be an exciting time of year for any child, but the same can?t always be said for adults, especially with today's tough economy.
See More
October 27, 2008 - Bayer HealthCare?s New Sterile Fill Facility Receives EMEA, FDA Licenses
BERKELEY, Calif. ?The European Medicines Agency (EMEA) has granted license approval to Bayer HealthCare LLC (Bayer) for its new sterile filling facility (SFF) on its Berkeley, Calif. campus.
See More
October 22, 2008 - Study Results: Multiple Sclerosis Patients Have Significant and Sustained Reduction in Disability and Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif?
CAMBRIDGE, MA and WAYNE, NJ ?Genzyme Corporation (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. today announced study results showing that patients with early relapsing-remitting multiple sclerosis (RRMS) taking once-yearly cycles of alemtuzumab reduced their risk of relapse by 74 percent and the risk of sustained accumulation of disability by 71 percent compared to patients treated with the active comparator Rebif? (high-dose interferon beta-1a).
See More
October 10, 2008 - FDA Approves Bayer HealthCare?s Kogenate? FS Treatment for Routine Prophylaxis in Children with Hemophilia A
BERKELEY, Calif., October 10, 2008 - Bayer HealthCare LLC announced today that the U.S. Food and Drug Administration (FDA) has approved routine prophylaxis with Kogenate? FS Antihemophilic Factor (Recombinant) to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage.
See More
September 20, 2008 - Five year data confirm that early treatment with Betaseron? at first sign of disease can delay progression to MS
MONTREAL, CANADA, September 20, 2008 - Bayer HealthCare Pharmaceuticals announced today that new data from its BENEFIT (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment)study confirm that early initiation of Betaseron? (interferon beta-1b) treatment in patients with a first event suggestive of multiple sclerosis (MS) significantly delayed the onset of clinically-definite MS (CDMS) by 37 percent (p=0.003) and McDonald MS by 45 percent (p<0.0001) over five years compared to delayed treatment.
See More
September 19, 2008 - New data presented at WCTRIMS supports the importance of early and sustained treatment with Betaseron?
MONTREAL, CANADA, September 19, 2008 - Data presented at the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS) demonstrated that early initiation of Betaseron? (interferon beta-1b) treatment had a greater impact on long-term outcomes, when compared to delayed treatment.
See More
September 15, 2008 - BAYER AND ONYX LAUNCH GLOBAL LIVER CANCER EDUCATIONAL PROGRAM
Stockholm, Sweden - September 15, 2008 - Addressing the growing incidence and general lack of awareness about liver cancer worldwide, Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. in partnership with leading advocacy organizations, today announced the launch of Living with Liver Cancer - the first international program designed to educate patients and caregivers worldwide about liver cancer signs and symptoms, risk factors and available approved treatment options, as well as methods for screening and diagnosis in at-risk populations.
See More
September 9, 2008 - Fashion Guru Nina Garcia Announces Winner of National Design Competition
Wayne, NJ - September 9, 2008 - Nina Garcia, judge of the Emmy-nominated series Project Runway, and the Step Up Women?s Network are proud to announce the winner of the "YAZ?: Step Up and Go Beyond" contest - aspiring handbag designer Elayne Mayes of Green Village, New Jersey.
See More
August 28, 2008 - SILVER MEDALIST JENNIE FINCH & RELATIONSHIP EXPERT STACY KAISER HELP "WIRED" COUPLES UNPLUG
Wayne, NJ - August 28, 2008 - Many couples live in a "wired" world, juggling lengthy to-do lists, jam-packed schedules, and the 24/7 demands of children and manage it all through cell phones, e-mail and other electronic devices.
See More
August 21, 2008 - BAYER AND ONYX BEGIN ENROLLMENT IN STORM TRIAL STUDYING NEXAVAR AS ADJUVANT THERAPY FOR PATIENTS WITH LIVER CANCER
Wayne, NJ and Emeryville, CA - August 21, 2008 - Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun enrolling patients in the STORM Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma trial.
See More
July 28, 2008 - Nexavar Approved for Liver Cancer in China
WAYNE, NJ and Emeryville, CA July 28, 2008 - Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the State Food and Drug Administration (SFDA) of China has approved Nexavar? (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer.
See More
July 23, 2008 - The New England Journal of Medicine Publishes Nexavar? Study Demonstrating Significant Improvement in Overall Survival in Patients with Liver Cancer
WAYNE, NJ and Emeryville, CA July 23, 2008 - Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that The New England Journal of Medicine published results of a Phase 3 trial demonstrating that Nexavar? (sorafenib) tablets decreased the absolute risk of death by 31 percent in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, versus patients who received placebo.
See More
July 8, 2008 - FDA Approves EOVIST? to Detect and Characterize Focal Liver Lesions
WAYNE, NJ July 8, 2008 - Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, announced today that the U.S. Food and Drug Administration (FDA) has approved EOVIST? (Gadoxetate Disodium) Injection, a gadolinium-based contrast agent, for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.
See More
July 2, 2008 - Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Leverkusen / Redwood City, California, USA, July 2, 2008 - Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen?s hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII.
See More
June 24, 2008 - Bayer concludes supply and licensing agreements
for Yasmin? and YAZ? with Barr for the United States
Berlin/Leverkusen, June 24, 2008 - Appeal of court decision invalidating Yasmin patent will continue. Further growth of Bayer?s Women?s Healthcare Business Unit expected.
See More
June 5, 2008 - Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
WAYNE, N.J., June 5, 2008 -Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).
See More
May 28, 2008 - Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen, New Survey Reveals
Denver, CO - May 28, 2008 - Nearly all people (97 percent) with multiple sclerosis (MS) who have started treatment say their commitment to managing their disease in every way possible is their prime motivation for staying on therapy, according to a new North American survey of people with MS, results of which were released today at the Consortium of Multiple Sclerosis Centers annual meeting in Denver.
See More
May 19, 2008 - Hemophilia Awareness and Fundraising Program Accelerates with Launch of 2008 Campaign
NEW YORK, NY - May 19, 2008 - The National Hemophilia Foundation (NHF) shifts into high gear today with the launch of Team Hemophilia on Tour, a fundraising and awareness program sponsored by Bayer HealthCare and supported by Andretti Green Racing.
See More
May 19, 2008 - Bayer Announces Availability of Reformulated Liquid Leukine?
Wayne, NJ - May 19, 2008 - Bayer HealthCare Pharmaceuticals Inc. announced today that a reformulation of the liquid Leukine? (sargramostim) 500 mcg vial has been approved by the United States Food and Drug Administration (FDA) and is now available for patients and physicians in the U.S.
See More
April 30, 2008 - Aspiring young designers give YAZ? birth control case a makeover
Nina Garcia of the Emmy-nominated series ?Project Runway? and Elle magazine is calling upon designer hopefuls everywhere to submit contemporary and fashionable packaging concepts for the oral contraceptive YAZ? (drospirenone & ethinyl estradiol).
See More
31 March 2008 - Bayer appeals invalidity ruling on its Yasmin? Patent
Leverkusen, March 31, 2008 ? Today, Bayer filed a Notice of Appeal in the United States District Court for the District of New Jersey
See More
11 March 2008 - Bayer HealthCare Pharmaceuticals Introduces VistaTrak™ An Innovative Contrast Media Management System
WAYNE, NJ – March 11, 2008 – Bayer HealthCare Pharmaceuticals Inc., a leader in diagnostic imaging, unveiled plans to launch VistaTrak™, an innovative contrast media management system that provides radiology departments with a new and powerful management tool to help enhance patient care and safety, optimize inventory management and improve billing accuracy.
See More
3 March 2008 - Court decides against Bayer's Yasmin® patent
See More
18 February 2008 - Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients with Non-Small Cell Lung Cancer
Wayne, NJ and Emeryville, CA – (February 18, 2008) – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar® (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stopped early following a planned interim analysis, when the independent Data Monitoring Committee (DMC) concluded that the study would not meet its primary endpoint of improved overall survival. The Phase 3 ESCAPE (Evaluation of Sorafenib, Carboplatin And Paclitaxel Efficacy in NSCLC) trial evaluated Nexavar when administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Safety events were generally consistent with those previously reported. However, higher mortality was observed in the subset of patients with squamous cell carcinoma of the lung treated with sorafenib and carboplatin and paclitaxel versus those treated with carboplatin and paclitaxel alone.
See More
5 February 2008 - Bayer HealthCare Awards Grant to Support Future Leaders of Bleeding Disorders Community
BERKELEY, Calif. – (February 5, 2008) – Bayer HealthCare today announced its donation of a $100,000 grant to help the National Hemophilia Foundation (NHF) fund activities for its National Youth Leadership Institute (NYLI), a program designed to develop the next generation of leaders within the bleeding disorders community. The contribution, made by the Bayer USA Foundation, marks the second year of support for this important program.
See More
23 January 2008 - Bayer Establishes US Special Access Program for Leukine® While Replacing Current Liquid Formulation
Wayne, NJ – Bayer HealthCare Pharmaceuticals Inc. announced today, following consultation with the United States Food and Drug Administration (FDA), that it will withdraw the current liquid formulation of Leukine® marketed in the US. This decision was made in light of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with the liquid Leukine 500 mcg vial which currently contains EDTA (edetate disodium).
See More
17 January 2008 - US Food and Drug Administration Approves RECOTHROMTM
See More
3 January 2008 - Expanded Labeling for MabCampath® in Europe
Berlin, January 3, 2008 – The European Commission has granted marketing authorization to MabCampath® (alemtuzumab) for the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.
See More
20 December 2007 - Marketing of Viadur? (leuprolide acetate implant) to Phase Out By April 2008
Other therapies available for patients
Wayne, NJ. ? Bayer HealthCare Pharmaceuticals Inc. announced today that after careful consideration, the company will discontinue marketing of Viadur? (leuprolide acetate implant) with Duros technology. Based on diminished market demand and growing manufacturing costs, Bayer HealthCare Pharmaceuticals has concluded that Viadur has limited long-term market viability. The decision to discontinue marketing of Viadur is not the result of safety or efficacy issues.
See More
05 December 2007 - Positive CHMP vote for Betaferon? label to include disability progression delay in patients with the earliest sign of MS
Betaferon? is first and only MS therapy to delay disability in patients treated after first MS attack
Berlin ? The Committee for Medicinal Products for Human Use (CHMP) has recommended to include new results from the landmark BENEFIT (BEtaferon in Newly Emerging multiple sclerosis For Initial T reatment) study in the Betaferon? (interferon beta-1b) label.
See More
20 November 2007 - Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
WAYNE, N.J., ? Bayer HealthCare Pharmaceuticals, Inc a leader in diagnostic imaging, announced today that the company has been awarded a three-year contract by MedAssets Supply Chain Systems, one of the nation's largest group purchasing organizations, to provide Magnevist(R) (gadopentetate dimeglumine) Injection contrast media to members of the MedAssets network. MedAssets serves more than 125 health systems, including 2,500 hospitals and 30,000 non-acute care healthcare providers
See More
19 November 2007 - Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Only Systemic Therapy Proven to Significantly Improve Overall Survival in Patients with Liver Cancer
Wayne, NJ and Emeryville, CA ? Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for Nexavar? (sorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC), or liver cancer.
See More
07 November 2007 - BRIGHT Results Show Less Pain and Higher Patient Satisfaction with Betaseron? than with Rebif?
Study shows injection site pain can negatively influence patient satisfaction with treatment
Wayne, NJ. ? Patients with relapsing-remitting multiple sclerosis (MS) treated with 250 mcg Betaseron (interferon beta-1b) experienced less injection site pain and fewer injection site reactions than those treated with 44 mcg Rebif. Moreover, among those who experienced injection site pain, significantly more patients on Rebif versus Betaseron said that pain negatively influences their satisfaction with treatment.
See More
05 November 2007 - Bayer Temporarily Suspends Global Trasylol? Marketing
Leverkusen, Germany and West Haven, CT, USA ? Following consultation with the German Federal Institute for Drugs and Medical Devices (BfArM), the U.S. Food and Drug Administration (FDA), Health Canada, and other health authorities, Bayer announced today that it has elected to temporarily suspend worldwide marketing of Trasylol? (aprotinin injection) until final results from the Canadian BART trial can be compiled, received and evaluated.
See More
30 October 2007 - Nexavar? Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Wayne, NJ and Emeryville, CA ? Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the European Commission has granted marketing authorization to Nexavar? (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer.
See More
29 October 2007 - BEYOND study: Results do not support regulatory filing for Betaferon? 500 mcg
Berlin, Germany - Bayer Schering Pharma AG, Germany, today announced top line results from the BEYOND (Betaferon Efficacy Yielding Outcomes of a New Dose) study, a large randomized trial of patients with relapsing-remitting multiple sclerosis (MS) to investigate the efficacy, tolerability and safety of a 500 mcg dose of Betaferon? (interferon beta-1b) compared to the standard 250 mcg Betaferon? dose and Copaxone? (glatiramer acetate).
See More
26 - October - New Survey Finds Technology Plays a Critical Role in the Lives of People with Multiple Sclerosis Yet Many Are Not Using It to Overcome Disease-Related Challenges
-- Affordable, Easy-to-Use Accessible Technology is Within Reach for People with MS --
DALLAS, OCTOBER 26, 2007 -- According to a new survey released this week in conjunction with the National MS Society's National Conference, many people living with multiple sclerosis (MS) who experience visual, dexterity, and cognitive challenges report that technology plays a vital role in helping them live with the disease. However, relatively few are using the assistive technologies that could help them overcome many of these challenges
See More
25 October 2007 - Bayer Issues Additional Guidance to Physicians on Trasylol?
Leverkusen, Germany and West Haven, CT, USA - Today Bayer announced new guidance to physicians and health care providers regarding the use of Trasylol? (aprotinin injection) in patients at an increased risk of blood loss and blood transfusion undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).
See More
23 October 2007 - Red Hot Flashbacks: Celebrity Stylist Yang & Red Hot Mamas Giblin Share How to Keep ?Cool? During ?Red Hot? Menopausal Moments
WAYNE, N.J. Oct 23, 2007 ? For many active, on-the-go women, menopause symbolizes uncomfortable and disruptive symptoms, such as hot flashes and night sweats.
See More
01 October 2007 - Bayer HealthCare Announces Positive Phase 2 Results for the VEGF Trap-Eye
Age-related Macular Degeneration (AMD) - Data presented at the Retina Society Conference in Boston
Leverkusen, Germany ?Bayer HealthCare and development partner Regeneron Pharmaceuticals, Inc. today announced positive results from a Phase 2 study evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD), one of the leading causes of blindness in adults.
See More
26 September 2007 - Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
CAMBRIDGE, Mass. and BERLIN, Germany ? Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).
See More
24 September 2007 - Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
Wayne, NJ and Emeryville, CA ? Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending to grant marketing authorization for Nexavar? (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer.
See More
20 September 2007 - FDA Approves Expanded Labeling for Campath? to Include First-line Treatment for Leading Form of Adult Leukemia
Study Data Demonstrated Improved Progression-free Survival with Campath
Cambridge, MA and Wayne, NJ ? Genzyme Corp. (Nasdaq: GENZ) and Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for Campath? (alemtuzumab) and granted regular approval for single-agent Campath for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).
See More
14 September 2007 - Bayer completes acquisition of U.S. biologics manufacturing facility from Novartis
Berlin, Germany ? Bayer Schering Pharma AG, Germany, has completed the acquisition of a biologics manufacturing facility in Emeryville, California from Novartis. Bayer will manufacture its multiple sclerosis drug Betaseron? at the Emeryville site, retain full control of all manufacturing and process technology used in the production of Betaseron? (interferon beta-1b) and has retained the employees associated with the manufacture of the product.
See More
12 September 2007 - FDA Advisory Committees Recommend Continued US Marketing Authorization for Trasylol
Committees also recommend further changes
to US Label for Trasylol and additional safety studies
Leverkusen, Germany; West Haven, CT, USA -- Today, the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to the U.S. Food and Drug Administration (FDA) held a meeting to discuss the risk /benefit profile of Trasylol? (aprotinin injection), a Bayer drug used in coronary artery bypass graft (CABG) surgery.
See More
27 August 2007 - Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Nexavar Significantly Improved Overall Survival in Phase 3
Asia-Pacific Liver Cancer Trial
Trial to be Stopped Early to Allow All Patients Access to Nexavar-
Wayne, NJ and Emeryville, CA - August 27, 2007 - Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a planned review by an independent data monitoring committee (DMC) found that Nexavar? (sorafenib) tablets significantly improved overall survival, progression free survival, and time to progression in an Asia-Pacific regional Phase 3 trial of patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer.
See More
20 August 2007 - Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Wayne, NJ and Emeryville, CA ? Bayer HealthCare Pharmaceuticals (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the supplemental New Drug Application (sNDA) for Nexavar? (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer, has been accepted for review and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
16 August 2007 - Bayer Reports Findings of Trasylol Independent Investigation
Investigator Report
Key Committees - Bayer Global Drug Safety
Leverkusen, Germany and West Haven, Connecticut, USA. Today, Bayer HealthCare reported findings of Mr. William Taylor's independent investigation on the i3 Drug Safety observational study on Trasylol? (aprotinin injection) to the U.S. Food and Drug Administration (FDA) and other relevant regulatory authorities and also conveyed actions the company has taken to ensure that this sort of mistake is never again repeated.
See More
2 August 2007 - Landmark Study in The Lancet:Patients Treated With Betaseron? After First MS Attack Experienced Significant Delay in MS Progression WAYNE, NJ ? August 2, 2007 ? Patients treated with Betaseron? (interferon beta-1b) shortly after their first clinical MS event or ?attack? showed a 40 percent lower risk of developing confirmed disability progression compared to patients in whom treatment was delayed.
See More
12 July 2007 - YAZ approved in the Netherlands as European Reference Member State
YAZ is the newest oral contraceptive innovation from Bayer Schering Pharma
Berlin ? Bayer Schering Pharma AG, Germany, announced today that the Dutch regulatory authorities have granted national approval for their new low dose 24-day oral contraceptive YAZ? in the Netherlands.
See More
09 July 2007 - Rivaroxaban shows superiority over current standard of care therapy
Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor, Shows a Significant Reduction in Deep Vein Thrombosis and Pulmonary Embolism Compared with Enoxaparin with Similarly Low Bleeding Rates
See More
29 June 2007 - Bayer HealthCare Announces New 2000 IU Vial Size for Kogenate? FS Treatments
Larger vial size, new Grab & Go package help to reduce reconstitution time and provide added convenience for people living with hemophilia A
Berkeley/USA ? Bayer HealthCare announces today the availability of a new 2000 IU (international unit) vial size in the United States for hemophilia A patients treated with Kogenate? FS, Antihemophilic Factor (Recombinant), and Kogenate? FS Antihemophilic Factor (Recombinant), with BIO-SET?, a Needleless Reconstitution System
See More
27 June 2007 - Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Nexavar is First Drug Therapy to Demonstrate Significant Survival Benefit in Liver Cancer
Wayne, NJ/USA ? Bayer HealthCare Pharmaceuticals Inc. (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar? (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.
See More
04 June 2007 - Phase 3 Study: Nexavar? Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Berlin - June 4, 2007 - Bayer HealthCare, a subsidiary of Bayer AG (NYSE:BAY), and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced thatNexavar? (sorafenib) tablets significantly extended overall survival in patients with hepatocellular carcinoma (HCC), or primary liver cancer versus those taking placebo by 44%.
See More
07 May 2007 - Bayer HealthCare and Intendis Announce Strategic Alliance To Co-promote YAZ® (drospirenone/ethinyl estradiol) for Treatment of Moderate Acne
Alliance Announced as Yaz Acne Clinical Trial Data Presented at 55th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG)
03 May 2007 - Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron®
Bayer HealthCare Pharmaceuticals announced today the results of three clinical studies with Betaseron (interferon beta-1b), presented this week at the American Academy of Neurology’s (AAN) 59th Annual Meeting, demonstrating early efficacy, long-term tolerability, and high patient satisfaction with treatment in patients with relapsing forms of multiple sclerosis (MS). See More
02 May 2007 - Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Interim analysis of Phase 2 comparative study showed significant results in favor of alemtuzumab versus Rebif®
01 May 2007 - First of Its Kind Data Show: Immediate Treatment of Early MS Patients with Betaseron®
Significantly Delayed Permanent Disability Risk to confirmed EDSS progression reduced by 40 percent compared to delayed treatment
11 April 2007 - Bayer supports the WHO in its fight against Chagas disease
Partnership with the World Health Organization (WHO) to continue
05 April 2007 - Indy Racing Season Drives New Support for Marco Andretti and Team Hemophilia
Indy Racing Season Drives New Support for Marco Andretti and Team Hemophilia
04 April 2007 - Genzyme Files for Expanded Label for Campath® as First-Line Treatment
Genzyme Files for Expanded Label for Campath® as First-Line Treatment For B-CLL Patients
04 April 2007 - Bayer HealthCare Pharmaceuticals Officially Launches in the United States
Bayer HealthCare Pharmaceuticals Officially Launches in the United States
02 April 2007 - Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment
The largest dataset ever analyzed on the relevance of NAbs to interferon beta therapy.
15 March 2007 - Werner Wenning at the Spring Financial News Conference
2006 a record year for Bayer
20 February 2007 - Bayer HealthCare strengthens presence in Eastern Europe
More than 200 staff for Marketing and Sales integrated in Russia, Belarus, the Ukraine and Kazakhstan
12 February 2007 - Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Trial To Be Stopped Early Based on Positive Outcome See More
08 February 2007 - EU-Approval for Continuous Infusion of KOGENATE® Bayer
Excellent Hemostatic Control Achieved.
